Literature DB >> 18185105

Monocyte chemoattractant protein-1 immunoreactivity in sensory ganglia and hindpaw after adjuvant injection.

Sang-Min Jeon1, Kyung-Min Lee, Eun-Sung Park, Young-Hoon Jeon, Hee-Jung Cho.   

Abstract

Monocyte chemoattractant protein-1 (MCP-1)/CCL2 is a member of the CC chemokine family that exhibits potent chemotactic activity for monocytes/macrophages. In the current study, the proportion of monocyte chemoattractant protein-1-immunoreactive (IR) neurons in the dorsal root ganglion (DRG) of rats was shown to increase markedly following adjuvant injection into the hindpaw. MCP-1-IR axon terminals were not found in the spinal cord or hindpaw of control or adjuvant-treated rats. Instead, the inflamed hindpaw dermis was infiltrated by numerous MCP-1-IR inflammatory cells. Following adjuvant injection, the majority of MCP-1-IR neurons in the DRG colocalized with IB4 binding. Our findings suggest that peripheral tissue inflammation induces increased MCP-1 expression in DRG neurons and this may be dependent upon glial cell line-derived neurotrophic factor.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18185105     DOI: 10.1097/WNR.0b013e3282f3c781

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  23 in total

1.  The majority of myelinated and unmyelinated sensory nerve fibers that innervate bone express the tropomyosin receptor kinase A.

Authors:  G Castañeda-Corral; J M Jimenez-Andrade; A P Bloom; R N Taylor; W G Mantyh; M J Kaczmarska; J R Ghilardi; P W Mantyh
Journal:  Neuroscience       Date:  2011-01-26       Impact factor: 3.590

Review 2.  Chemokines, neuronal-glial interactions, and central processing of neuropathic pain.

Authors:  Yong-Jing Gao; Ru-Rong Ji
Journal:  Pharmacol Ther       Date:  2010-02-01       Impact factor: 12.310

3.  Breast cancer-induced bone remodeling, skeletal pain, and sprouting of sensory nerve fibers.

Authors:  Aaron P Bloom; Juan M Jimenez-Andrade; Reid N Taylor; Gabriela Castañeda-Corral; Magdalena J Kaczmarska; Katie T Freeman; Kathleen A Coughlin; Joseph R Ghilardi; Michael A Kuskowski; Patrick W Mantyh
Journal:  J Pain       Date:  2011-04-15       Impact factor: 5.820

4.  Involvement of spinal chemokine CCL2 in the hyperalgesia evoked by bone cancer in mice: a role for astroglia and microglia.

Authors:  Marta Pevida; Sara González-Rodríguez; Ana Lastra; Olivia García-Suárez; Agustín Hidalgo; Luis Menéndez; Ana Baamonde
Journal:  Cell Mol Neurobiol       Date:  2014-01       Impact factor: 5.046

Review 5.  Insights into the regulation of chemokine receptors by molecular signaling pathways: functional roles in neuropathic pain.

Authors:  Fletcher A White; Richard J Miller
Journal:  Brain Behav Immun       Date:  2010-03-27       Impact factor: 7.217

6.  Excess risk of temporomandibular disorder associated with cigarette smoking in young adults.

Authors:  Anne E Sanders; William Maixner; Andrea G Nackley; Luda Diatchenko; Kunthel By; Vanessa E Miller; Gary D Slade
Journal:  J Pain       Date:  2011-10-26       Impact factor: 5.820

7.  Contribution of the chemokine (C-C motif) ligand 2 (CCL2) to mechanical hypersensitivity after surgical incision in rats.

Authors:  Christopher M Peters; James C Eisenach
Journal:  Anesthesiology       Date:  2010-05       Impact factor: 7.892

8.  CCL2 released at tumoral level contributes to the hyperalgesia evoked by intratibial inoculation of NCTC 2472 but not B16-F10 cells in mice.

Authors:  Marta Pevida; Sara González-Rodríguez; Ana Lastra; Agustín Hidalgo; Luis Menéndez; Ana Baamonde
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-09-14       Impact factor: 3.000

Review 9.  Chemokines as pain mediators and modulators.

Authors:  Fletcher A White; Natalie M Wilson
Journal:  Curr Opin Anaesthesiol       Date:  2008-10       Impact factor: 2.706

Review 10.  Gliopathic pain: when satellite glial cells go bad.

Authors:  Peter T Ohara; Jean-Philippe Vit; Aditi Bhargava; Marcela Romero; Christopher Sundberg; Andrew C Charles; Luc Jasmin
Journal:  Neuroscientist       Date:  2009-10       Impact factor: 7.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.